In the United States, [Ga-68]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first Ga-68-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [Ga-68]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide Ga-68 with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response.